Abstract
Ibrutinib(IBR) is an irreversible Bruton's tyrosine kinase inhibitor and has been classified as the Biopharmaceutical Classification System (BCS) clas......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
